{"id":"placebo-matching-lenvatinib","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hypertension"},{"rate":"35-45","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Decreased appetite"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Vomiting"},{"rate":"20-30","effect":"Weight loss"},{"rate":"20-30","effect":"Proteinuria"},{"rate":"15-25","effect":"Palmar-plantar erythrodysesthesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib inhibits multiple receptor tyrosine kinases including FGFR, VEGFR, RET, and KIT, thereby suppressing tumor cell proliferation, survival, and the formation of new blood vessels that feed tumors. By targeting these pathways simultaneously, it provides broad anti-cancer activity across multiple tumor types. This placebo-matching formulation is used in clinical trials to maintain blinding while delivering the active lenvatinib dose.","oneSentence":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks signaling pathways critical for tumor growth and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:00.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radioiodine-refractory differentiated thyroid cancer"},{"name":"Unresectable hepatocellular carcinoma"},{"name":"Advanced renal cell carcinoma (in combination with pembrolizumab)"},{"name":"Endometrial carcinoma (in combination with pembrolizumab)"}]},"trialDetails":[{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT03829319","phase":"PHASE3","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-25","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":761},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT04716933","phase":"PHASE3","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":201},{"nctId":"NCT01525394","phase":"PHASE1","title":"A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-12","conditions":"Refractory Solid Tumors, Lymphomas","enrollment":52},{"nctId":"NCT01321554","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-03-17","conditions":"Thyroid Cancer","enrollment":392},{"nctId":"NCT02966093","phase":"PHASE3","title":"A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-01-11","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":151},{"nctId":"NCT02702388","phase":"PHASE2","title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-06-08","conditions":"Thyroid Cancer","enrollment":241},{"nctId":"NCT01529112","phase":"PHASE2","title":"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Non-Small Cell Lung Cancer","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching lenvatinib","genericName":"Placebo matching lenvatinib","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks signaling pathways critical for tumor growth and angiogenesis. Used for Radioiodine-refractory differentiated thyroid cancer, Unresectable hepatocellular carcinoma, Advanced renal cell carcinoma (in combination with pembrolizumab).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}